High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma

International Journal of Cancer

Volumn 123, Issue 4, 2008, Pages 846-851

  Kuvaja, Paula ^a   Talvensaari Mattila, Anne ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; ELISA; Prognosis; TIMP 1

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; BREAST TUMOR; CANCER STAGING; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PREOPERATIVE CARE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 47049125329     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23531     Document Type: Article

References (24)

1. Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H, Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. American society of clinical oncology tumor markers expert panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 2001;19:1865-78
2. Würtz SØ, Schrohl AS, Sorensen N, Lademann U, Christensen IJ, Mouridsen H, Brünner N. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr-Relat Cancer 2005;12:215-27.
3. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signalling. Cancer Metastasis Rev 2006;25:99-113.
4. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
5. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteianses-1. J Clin Invest 1998;102:2002-10.
6. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Nenyon C, Iredale JP. Inhibition of apoptosis of cativated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-76.
7. Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 2004;72:82-8.
8. Guo LJ, Luo XH, Xie H, Zhou HD, Yuan LQ, Wang M, Liao EY. Tissue inhibitor of matrix metalloproteinase-1 suppresses apoptosis of mouse bone marrow stromal cell line MBA-1. Calcif Tissue Int 2006;78:285-92.
9. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteianse-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-75.
10. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003;278:40364-72.
11. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells form extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65:898-906.
12. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003;312:1196-201.
13. Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology 2005;68:196-203.
14. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-13.
15. Schrohl AS, Holten-Andersen MN, Peters H, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-98.
16. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator in breast carcinoma. Breast Cancer Res Treat 2005;89:29-34.
17. Schrohl AS, Meijer-van Gelder M, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen H, Brünner N, Foekens JA. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006;12:7054-8.
18. Davidsen ML, Würtz S, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Cancer 2006;95:1114-20.
19. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-11.
20. Altman DG. Practical statictics for medical research. London: Chapman and Hall, 1991.426-33.
21. Kuvaja P, Würtz SØ, Talvensaari-Mattila A, Brünner N, Pääkkö P, Turpeenniemi-Hujanen T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma-a validation study. Cancer Biomark 2007;3:293-300.
22. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Camey W. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007;109:1933-9.
23. Giannelli G, Erriguez R, Fransvea E, Daniele A, Treotoli P, Schittuli F, Grano M, Quaranta M, Antonachi S. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004;109:782-5.
24. Yamazaki M, Akahane T, Buck T, Yoshiji H, Gomez DE, Shcoeffner DJ, Okajima E, Harris SR, Bunce OR, Thorgeisson SS, Thorgeisson UP. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppressess growth of mammary carcinomas in transgenic mice. Carcinogenesis 2004;25:1735-46.